Display Settings:

Format

Send to:

Choose Destination
Cancer Cell. 2012 May 15;21(5):614-25. doi: 10.1016/j.ccr.2012.03.042.

Allele-specific p53 mutant reactivation.

Author information

  • 1The Cancer Institute of New Jersey, New Brunswick, NJ 08903, USA.

Abstract

Rescuing the function of mutant p53 protein is an attractive cancer therapeutic strategy. Using the National Cancer Institute's anticancer drug screen data, we identified two compounds from the thiosemicarbazone family that manifest increased growth inhibitory activity in mutant p53 cells, particularly for the p53(R175) mutant. Mechanistic studies reveal that NSC319726 restores WT structure and function to the p53(R175) mutant. This compound kills p53(R172H) knockin mice with extensive apoptosis and inhibits xenograft tumor growth in a 175-allele-specific mutant p53-dependent manner. This activity depends upon the zinc ion chelating properties of the compound as well as redox changes. These data identify NSC319726 as a p53(R175) mutant reactivator and as a lead compound for p53-targeted drug development.

Copyright © 2012 Elsevier Inc. All rights reserved.

Comment in

PMID:
22624712
[PubMed - indexed for MEDLINE]
PMCID:
PMC3366694
Free PMC Article

Images from this publication.See all images (6)Free text

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk